Skip navigation
Skip navigation

Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen

Silva, Diego; Charlton, Brett; Cowden, William; Petrovsky, Nikolai

Description

The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of...[Show more]

dc.contributor.authorSilva, Diego
dc.contributor.authorCharlton, Brett
dc.contributor.authorCowden, William
dc.contributor.authorPetrovsky, Nikolai
dc.date.accessioned2015-12-13T23:11:47Z
dc.date.available2015-12-13T23:11:47Z
dc.identifier.issn0077-8923
dc.identifier.urihttp://hdl.handle.net/1885/87747
dc.description.abstractThe most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of administration, development of surrogate immune markers, and elucidation of the mechanism of protection. The mechanism whereby QFA protects against diabetes currently is not known. The elucidation of the mechanism should help identify the optimal way in which to administer QFA to provide diabetes protection. It may also assist the development of even more potent immunostimulatory vaccines.
dc.publisherNew York Academy of Sciences
dc.sourceAnnals of the New York Academy of Sciences
dc.subjectKeywords: BCG vaccine; biological marker; immunostimulating agent; placebo; q fever complement fixing antigen; recombinant antigen; unclassified drug; vaccine; autoimmune disease; clinical trial; conference paper; controlled clinical trial; diabetes control; double Autoimmune diabetes; Immunostimulation; QFA; Type 1 diabetes; Vaccine development
dc.titlePrevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen
dc.typeJournal article
local.description.notesImported from ARIES
local.description.refereedYes
local.identifier.citationvolume1005
dc.date.issued2003
local.identifier.absfor110703 - Autoimmunity
local.identifier.ariespublicationMigratedxPub17173
local.type.statusPublished Version
local.contributor.affiliationSilva, Diego, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationCharlton, Brett, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationCowden, William, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationPetrovsky, Nikolai, College of Medicine, Biology and Environment, ANU
local.bibliographicCitation.startpage423
local.bibliographicCitation.lastpage430
local.identifier.doi10.1196/annals.1288.072
dc.date.updated2015-12-12T08:28:59Z
local.identifier.scopusID2-s2.0-1942474600
CollectionsANU Research Publications

Download

There are no files associated with this item.


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator